The Effect of Combination of Mosapride and DPP-4 Inhibitor on Plasma Concentration of Incretin Hormones

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2014
The aim of this study is to investigate the effects of combined administration of mosapride as modulator of gastrointestinal motility and DPP-4 inhibitor on secretion of gut hormone such as glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP), and oral glucose tolerance. Additionally, change in lipid profile and insulin secretion will be also assessed.
Epistemonikos ID: 20dec2aaaac0978f18d28915eb92e9baf7e62f5b
First added on: May 11, 2024